orphan drugs


Also found in: Dictionary, Encyclopedia.
Related to orphan drugs: orphan disease

or·phan pro·ducts

drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in either common or rare diseases but that are not considered commercially viable.
Synonym(s): orphan drugs

or·phan prod·ucts

(ōr'făn prod'ŭkts)
Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in treating rare diseases but are not considered commercially viable.

orphan drugs

A drug used to treat a rare disease and for which the market is so small that manufacturers have little incentive to go to the expense of producing them. In1983 US legislation provided financial incentives, in the form of tax credits and 7 year exclusive rights, to firms willing to produce such drugs. This has been effective and, by mid-2003, 229 orphan drugs were available.
References in periodicals archive ?
The orphan drugs market growth is fueled by the factors such as extended market exclusivity and government incentives for orphan medicine.
Identify opportunities: Analysis of the leading companies in the orphan drug space, examining their portfolios and orphan drugs in their pipelines.
com/research/g8q842/global_orphan) has announced the addition of the "Global Orphan Drug Market Future Outlook 2020" report to their offering.
The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals.
6 million in 1987 alone on research and development of orphan drugs.
Research: innovative areas of research such as antisense therapy, gene therapy, and cellular therapy in which orphan drugs are playing a key role.
The FDA's Office of Orphan Drug Products Development reviews applications for Orphan Drug status to support development of medicines for underserved patient populations, or rare disorders that affect fewer than 200,000 people in the United States.
In US, the research & development of orphan drugs is facilitated by public programs, government regulations, and policies.
This report reviews the orphan drug regulations in 10 Asian countries and discusses various business issues related to orphan drugs in the region.
The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.
With many companies facing the patent cliff, orphan drugs offer potentially high returns, lower development costs and less intense competition.
The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols.